Breaking News Instant updates and real-time market news.

MDCO

The Medicines Co.

$48.28

0.33 (0.69%)

14:20
09/12/19
09/12
14:20
09/12/19
14:20

The Medicines Co. up 2% in afternoon trading

Reorg has issued a report discussing The Medicines Co. being a potential takeover target, contacts tell The Fly. The stock is up 2% in afternoon trading as the report is being circulated among traders.

MDCO The Medicines Co.
$48.28

0.33 (0.69%)

09/03/19
SBSH
09/03/19
NO CHANGE
Target $55
SBSH
Buy
The Medicines Co. price target raised to $55 from $48 at Citi
Citi analyst Joel Beatty raised his price target for The Medicines Co. to $55 from $48 following this weekend's detailed Phase 3 inclisiran data. The results suggest that inclisran is comparable on safety and efficacy to the approved PCSK9 antibody agents, Beatty tells investors in a research note. The analyst's new price target assumes a 100% probability of success for the drug. He keeps a Buy rating on The Medicines Co.
09/03/19
OPCO
09/03/19
NO CHANGE
Target $60
OPCO
Outperform
The Medicines Co. price target raised to $60 from $52 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for The Medicines Co. to $60 from $52 after the company presented details from the Phase 3 ORION-11 trial at ESC after recent topline results. The analyst believes the results "significantly de-risk" ORION-9 and -10 data to read-out sequentially in late Q3, and views The Medicines Co. as an "attractive" potential M&A target. Based on positive ORION-11 details, he also increased his Probability of Success for inclisiran to 80% from 70%. Olson reiterates an Outperform rating on the shares.
09/03/19
JPMS
09/03/19
NO CHANGE
Target $49
JPMS
Overweight
The Medicines Co. price target raised to $49 from $39 at JPMorgan
JPMorgan analyst Jessica Fye raised her price target for The Medicines Co. to $49 from $39 and keeps an Overweight rating on the shares. The analyst views the "strong" Orion-11 results as de-risking for the additional Phase III trials. With little to pick into in the data," investor focus should shift to the commercial potential for inclisiran and the extent to which "strategic appetite exists for the asset," Fye tells investors in a research note. She continues to see a "substantial" market opportunity for inclisiran and are raised her 2030 sales forecast to $2.1B.
09/03/19
STFL
09/03/19
NO CHANGE
Target $116
STFL
Buy
Alnylam data broadly support inclisiran as approvable drug, says Stifel
After Alnylam (ALNY) partner The Medicine Co. (MDCO) presented Phase 3 data on inclisiran at the European Society of Cardiology Congress, Stifel analyst Paul Matteis said the efficacy data were positive, but the focus is really on safety and "encouragingly" the adverse events, incidence of death, and serious adverse events all occurred at similar rates on inclisiran versus placebo. The analyst, who believes the data broadly support inclisiran as an approvable drug, also thinks the results validate Alnylam's recent efforts in non-orphan areas. Matteis, who noted that Alnylam will receive up to a 20% royalty on inclisiran sales, has a Buy rating and $116 price target on Alnylam shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.